Skip to main content

Table 6 Demographical, oncological, and echocardiographic data of patients who had an abnormally elevated level of plasma NT-pro BNP in the follow-up visit

From: The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients

Patients no. Pt.7 Pt.12 Pt.13 Pt.19 Pt.38
Age (years) 53 65 47 60 58
Site of cancer R L L R R
FH of cancer YES NO NO NO NO
Type of cancer IDC II IDC II IDC II IDC II IDC II
TNM staging 2,1,0 2,1,0 2,0,0 2,1,0 2,1,0
Progesterone receptors Positive Positive Positive Negative Negative
Estrogen receptors Negative Negative Positive Negative Negative
HER2 Positive Positive Positive Positive Positive
Chemotherapy type 1 A E E A E
Dose in mg/cycle 110 100 160 90 150
Cumulative dose in mg (after 3 cycles) 330 300 480 270 450
Chemotherapy type 2 C C C C C
Dose in mg per cycle 1100 1000 1200 900 1000
Cumulative dose in mg (after 3 cycles) 3300 3000 3600 2700 3000
Timing of surgery Before chemotherapy Before chemotherapy Before chemotherapy Before chemotherapy Before chemotherapy
2D LVEF (baseline) 57 64 60 60 59
2D LVEF (FU) 64 54 59 58 55
Relative change of 2D LVEFa + 0.12 − 0.16 − 0.02 − 0.03 − 0.07
2D-GLS (Baseline) 21 20 22 16 27
2D-GLS (FU) 17 15 18 14 -18
Relative change of 2D-GLSa − 0.19 − 0.25 − 0.18 − 0.13 − 0.33
3D LVEF (Baseline) 55.8 57.7 60.2 60.7 69.0
3D LVEF (FU) 56.0 57.0 60.0 62.0 59.0
Relative change of 3D-LVEFa +0.004 − 0.012 − 0.003 +0.021 − 0.145
NT-pro BNP, pg/ml (Baseline) 36.5 66 81.5 459 34.3
NT-pro BNP, pg/ml (FU) 342 459 324.6 977.5 208
Relative change of NT-proBNP +8.4 +6.0 +3.0 +1.1 +5.1
  1. FH family history, TNM tumor lymph node metastasis, HER2 human epidermal growth factor receptor 2, CH chemotherapy, R right, L left, IDC invasive ductal carcinoma, A doxorubicin, E epirubicin, C cyclophosphamide, PRE surgery before chemotherapy
  2. aRelative change was calculated as follows (the FU value − the baseline value/the baseline value)